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Abstract
Background: Lung ischemia-reperfusion (IR) injury leads to significant morbidity and mortality
which remains a major obstacle after lung transplantation. However, the role of various subset(s)
of lung cell populations in the pathogenesis of lung IR injury and the mechanisms of cellular
protection remain to be elucidated. In the present study, we investigated the effects of adenosine
A2A receptor (A2AAR) activation on resident lung cells after IR injury using an isolated, buffer-
perfused murine lung model.
Methods: To assess the protective effects of A2AAR activation, three groups of C57BL/6J mice
were studied: a sham group (perfused for 2 hr with no ischemia), an IR group (1 hr ischemia + 1 hr
reperfusion) and an IR+ATL313 group where ATL313, a specific A2AAR agonist, was included in
the reperfusion buffer after ischemia. Lung injury parameters and pulmonary function studies were
also performed after IR injury in A2AAR knockout mice, with or without ATL313 pretreatment.
Lung function was assessed using a buffer-perfused isolated lung system. Lung injury was measured
by assessing lung edema, vascular permeability, cytokine/chemokine activation and
myeloperoxidase levels in the bronchoalveolar fluid.
Results: After IR, lungs from C57BL/6J wild-type mice displayed significant dysfunction (increased
airway resistance, pulmonary artery pressure and decreased pulmonary compliance) and significant
injury (increased vascular permeability and edema). Lung injury and dysfunction after IR were
significantly attenuated by ATL313 treatment. Significant induction of TNF-α, KC (CXCL1), MIP-2
(CXCL2) and RANTES (CCL5) occurred after IR which was also attenuated by ATL313 treatment.
Lungs from A2AAR knockout mice also displayed significant dysfunction, injury and cytokine/
chemokine production after IR, but ATL313 had no effect in these mice.
Conclusion: Specific activation of A2AARs provides potent protection against lung IR injury via
attenuation of inflammation. This protection occurs in the absence of circulating blood thereby
indicating a protective role of A2AAR activation on resident lung cells such as alveolar macrophages.
Specific A2AAR activation may be a promising therapeutic target for the prevention or treatment
of pulmonary graft dysfunction in transplant patients.
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Background
Ischemia-reperfusion (IR)-induced lung injury remains
the major cause of primary graft failure after lung trans-
plantation [1,2]. IR injury causes significant mortality and
morbidity in the early post-operative period and is
reported to be an independent predictive factor for the
development and progression of bronchiolitis obliterans
syndrome, which is the most common cause of death after
lung transplantation [1,3]. We have previously demon-
strated that alveolar macrophage activation [4] and alveo-
lar type II epithelial cell activation [5] are associated with
the induction of lung IR injury. An event which follows
macrophage and epithelial cell activation is neutrophil
activation and infiltration into lung tissue which results in
severe pulmonary dysfunction in the early post-transplant
period [6-8]. Pulmonary IR injury also entails the induc-
tion of pro-inflammatory cytokines and chemokines
[9,10], and the contribution of TNF-α, IL-1β, IL-6 and KC
(CXCL1) in the genesis and progression of lung IR injury
has been demonstrated [5,11,12].
One major anti-inflammatory mechanism after lung
injury is mediated by the release of adenosine [13]. Ade-
nosine receptors are found on various cell types, and the
activation of these receptors often results in suppression
of inflammatory function [14-17]. The A2A  adenosine
receptor (A2AAR) is one of four subtypes of the G protein-
coupled adenosine receptor family which includes A1,
A2A, A2B and A3. Adenosine receptor sub-classification has
shown specifically that activation of A2AAR produces anti-
inflammatory responses and prevents leukocyte adhesion
[18,19]. Recent studies have shown that pharmacologic
activation of A2AAR restores functional integrity in renal,
cardiac, hepatic and spinal cord IR injury models [20-25].
A2AAR activation during reperfusion has also been shown
to ameliorate lung IR injury while decreasing cellular and
molecular inflammatory markers [26,27]. A2AARs are pre-
dominantly expressed on inflammatory cells including
neutrophils, mast cells, macrophages, T cells, monocytes
and platelets [28,29]. The attenuation of IR injury by
A2AAR activation is postulated to involve a purinergic reg-
ulatory process whereby the A2AAR coupled to a stimula-
tory G protein leads to an increase in cyclic adenosine
monophosphate (cAMP), thereby resulting in reduced
cytokine release and inactivation of inflammatory cells
[30,31].
This study focuses on the role of resident lung leukocytes
in IR injury and the effects of A2AAR activation on these
cells using an isolated, buffer-perfused mouse model of
lung IR injury. This model allows the investigation of spe-
cific and direct effects of A2AAR activation on lung func-
tion independent of circulating platelets and neutrophils.
The anti-inflammatory actions of selective A2AAR agonists
have been attributed to circulating leukocytes in previous
studies. However, in the present study, we hypothesize
that specific activation of A2AAR on resident lung cells
would attenuate pulmonary injury and dysfunction after
IR despite the absence of circulating platelets and leuko-
cytes from blood reperfusion.
Methods
Animals and study design
We utilized 8–10 week old wild-type (WT) C57BL/6J mice
(The Jackson Laboratory, Bar Harbor, ME) and A2AAR
knockout (KO) mice congenic to C57BL/6J [32]. Three
groups of animals were studied (n = 6/group); a sham
group, an IR group and an IR+ATL313 group. Lungs in the
IR group were subjected to 1 hr ischemia followed by 1 hr
reperfusion with Krebs-Henseleit buffer. As a control,
Sham lungs received 2 hr reperfusion without ischemia,
and the final 1 hr of perfusion in the sham lungs were
compared with the 1 hr of reperfusion in the IR group. The
IR+ATL313 group was identical to the IR group except that
ATL313 (30 nM) was added to the perfusate buffer at the
beginning of the reperfusion period. ATL313 (a gift from
Adenosine Therapeutics, LLC, Charlottesville, VA) is a
potent and highly specific activator of A2AAR [32]. The
dose of ATL313 used in this study (30 nM) had no signif-
icant effects on pulmonary function or hemodynamics in
lungs from sham animals (data not shown). A2AAR KO
mice were also subjected to IR and IR+ATL313 as
described above. This study was conducted under proto-
cols approved by the University of Virginia's Institutional
Animal Care and Use Committee. All animals received
humane care in compliance with the "Principles of Labo-
ratory Animal Care" formulated by the National Society
for Medical Research, and "The Guide for the Care and
Use of Laboratory Animals", prepared by the National
Academy of Science and published by the National Insti-
tutes of Health.
Isolated, buffer-perfused lung IR model
For this study, we used an isolated, buffer-perfused mouse
lung system (Hugo Sachs Elektronik, March-Huggstetten,
Germany) as previously described by our laboratory [4].
Mice were anesthetized with ketamine and xylazine. A tra-
cheotomy was performed, and animals were ventilated
with room air at 100 breaths/min at a tidal volume of 7
μl/g body weight with a positive end expiratory pressure
of 2 cm H2O using the MINIVENT mouse ventilator
(Hugo Sachs Elektronik, March-Huggstetten, Germany). A
midline abdominal incision was made, and the inferior
vena cava was cannulated with a 30-gauge needle and
injected with 500 units of heparin. Animals were exsan-
guinated by inferior vena caval transection. The subdia-
phragmatic portion of the animal was excised and
discarded. The anterior chest plate was removed, exposing
the lungs and heart. A 4-0 silk suture was passed behind
the pulmonary artery (PA) and the aortic root. A partial
half-knot was created with the suture, leaving room for
the cannula to be passed into the PA. A small curvilinearRespiratory Research 2009, 10:58 http://respiratory-research.com/content/10/1/58
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incision was made in the right ventricular outflow tract
with the perfusate flowing at 0.2 ml/min, and the PA can-
nula was passed through the pulmonary valve into the PA.
The partial half-knot was then tightened. The left ventricle
was immediately vented with a small incision at the apex
of the heart. The mitral apparatus was carefully dilated
and the left atrial cannula was passed through the mitral
valve into the left atrium. The placement of the left atrial
and the PA cannulas were further confirmed by pressure
tracings generated by the PULMODYN data acquisition
system (Hugo Sachs Elektronik). The lungs were then per-
fused at a constant flow of 60 μl/g body wt/min with
Krebs-Henseleit buffer (Sigma-Aldrich, St. Louis, MO)
containing 0.1% glucose and 0.3% HEPES (335–340
mOsmol/kg H2O). The Krebs solution was prepared to
mimic mixed venous blood using an oxygenator (Living
Systems Instrumentation, Burlington, VT) with titrated
gases generating a pH = 7.35–7.40, a pO2 = 60–70 mmHg,
and a pCO2 = 50–60 mmHg. The buffered perfusate and
isolated lungs were maintained at 37°C throughout the
experiment by use of a circulating water bath.
Isolated lungs were allowed to equilibrate on the appara-
tus during a 15-min stabilization period. After equilibra-
tion, ventilation was decreased to 50 breaths/min, and the
fraction of inspired oxygen was decreased to <1%. To ini-
tiate the ischemic period, hypoxic ventilation was main-
tained with 95% nitrogen and 5% carbon dioxide, and
perfusion was arrested. After 60 min of ischemia and
hypoxic ventilation, perfusion and room air ventilation
were then resumed to initiate the reperfusion period.
Hemodynamic and pulmonary function parameters were
continuously recorded throughout the reperfusion period
by the PULMODYN data acquisition system (Hugo Sachs
Elektronik). Ventilation with hypoxic gas rather than stop-
ping ventilation altogether during ischemia was per-
formed to avoid atelectasis while still maintaining
ischemia. Atelectasis and reexpansion has been shown to
induce injury involving edema, free radical generation,
and apoptosis [33,34]. This reexpansion-induced injury
could obscure the effects of IR injury, an issue we wished
to avoid.
Bronchoalveolar lavage (BAL) fluid collection
After perfusion, lungs were lavaged with 0.5 ml saline via
tracheotomy. This procedure was performed three times,
and the fluid was pooled together. An average of 1.2 ml
total BAL fluid was collected from each mouse. BAL fluid
was centrifuged at 4°C (1500 g  for 15 min), and the
supernatant was stored at -80°C.
Cytokine and chemokine protein analysis
Cytokine and chemokine protein content in BAL fluid was
quantified using the Bioplex Bead Array technique using a
mouse-specific multiplex cytokine panel assay (Bio-Rad
Laboratories, Hercules, CA). The microplates were ana-
lyzed by the Bioplex array reader which is a fluorescent-
based flow cytometer employing a specific bead-based
multiplex technology, each of which is conjugated with a
reactant specific for a different target cytokine. The array
reader quantifies the magnitude of the bead fluorescence
intensity associated with each target protein.
Lung wet/dry weight ratio
Lung wet/dry weight ratio was used as an indicator of pul-
monary edema using separate groups of animals (n = 5/
group). The lower lobe of the right lung from each animal
was harvested, weighed and placed in a vacuum oven (at
54°C) until a stable, dry weight was achieved. The ratio of
lung wet weight to dry weight was then calculated.
Vascular permeability assay
As another indicator of lung injury, lung vascular perme-
ability was assessed using separate groups of animals (n =
5/group). At the completion of reperfusion, the perfusion
buffer (Krebs Henseleit solution) was replaced with 30
mg/ml bovine serum albumin (BSA) solution (in PBS),
and the lungs were perfused for an additional 5 min at the
same flow rate as during reperfusion. After this, the BSA
solution was changed back to Krebs Henseleit solution,
and perfusion was continued for an additional 5 min to
wash out the BSA solution from the lung vasculature.
Using a BSA ELISA kit (Immunology Consultants Labora-
tory, OR), BSA concentration in BAL fluid was measured
according to the manufacturer's instructions.
Myeloperoxidase (MPO) measurement
MPO, which is expressed in neutrophils, was measured in
BAL fluid as an indicator of neutrophil infiltration into
alveolar spaces. An MPO ELISA kit (Cell Sciences, Canton,
MA) was utilized as instructed by the manufacturer.
Statistical analysis
Values are presented as the mean ± standard error of the
mean (SEM). Analysis of variance (ANOVA) was used to
determine if significant differences existed between
groups. Bonferroni's HSD multiple comparison test was
used to determine which groups were significantly differ-
ent when the ANOVA results were significant. Data was
considered significant when p < 0.05.
Results
Lung function after IR
Using the isolated, buffer-perfused mouse model of IR,
lung function in WT mice was measured during the 1 hr
reperfusion period after ischemia and compared to Sham
lungs. Significant lung dysfunction occurred after IR as
shown in Figure 1. At the end of reperfusion, IR lungs
exhibited significantly increased pulmonary artery pres-
sure (16.5 ± 0.26 vs. 8.78 ± 0.56 cm H2O), increased air-Respiratory Research 2009, 10:58 http://respiratory-research.com/content/10/1/58
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way resistance (2.74 ± 0.05 vs. 0.87 ± 0.02 cm H2O/μl/
sec) and reduced pulmonary compliance (1.54 ± 0.05 vs.
4.34 ± 0.19 μl/cm H2O) compared to Sham (p < 0.01).
Lung dysfunction after IR is attenuated by A2AAR 
activation
To investigate the effects of A2AAR activation on lungs
undergoing IR injury, ATL313, a specific A2AAR agonist,
was administered during reperfusion. A significant
improvement in lung function was observed in the
ATL313-treated lungs compared to lungs undergoing IR
alone (Figure 1). At the end of reperfusion, ATL313 signif-
icantly reduced pulmonary artery pressure (8.37 ± 0.55 vs.
16.5 ± 0.26 cm H2O), reduced airway resistance (0.75 ±
0.09 vs. 2.74 ± 0.05 cm H2O/μl/sec) and increased pulmo-
nary compliance (3.18 ± 0.09 vs. 1.54 ± 0.05 μl/cm H2O)
compared to IR alone (p < 0.01). In fact, lung function
after IR in ATL313-treated lungs was comparable to Sham
lungs.
ATL313 specifically acts on A2AAR
To eliminate the possibility that ATL313 could have
effects secondary to A2AAR activation, lung function was
measured after IR in A2AAR KO mice with or without treat-
ment with ATL313. Lung function was not different
between sham A2AAR KO mice and sham WT mice (data
not shown). Similar to WT mice, significant dysfunction
occurred in lungs from A2AAR KO mice after IR (Figure 2).
At the end of reperfusion, lungs from A2AAR KO mice dis-
played significantly increased pulmonary artery pressure
(14.7 ± 0.83 vs. 8.78 ± 0.56 cm H2O), increased airway
resistance (1.89 ± 0.09 vs. 0.87 ± 0.02 cm H2O/μl/sec) and
decreased pulmonary compliance (2.32 ± 0.09 vs. 4.34 ±
0.19 μl/cm H2O) versus WT Sham (p < 0.01). Further-
more, treatment of A2AAR KO mice with ATL313 did not
result in any improvement in lung function, and these
mice displayed no significant difference in lung function
compared to A2AAR KO mice undergoing IR alone (Figure
2).
A2AAR activation inhibits lung IR injury
To assess lung injury after IR, vascular permeability (as
measured by BSA content in BAL fluid) and pulmonary
edema (as measured by wet/dry weight) were assessed at
the end of the reperfusion period. A significant increase in
vascular permeability (Figure 3A) and pulmonary edema
(Figure 3B) occurred after IR in lungs from WT and A2AAR
KO mice versus sham (p < 0.001). ATL313 significantly
decreased vascular permeability and pulmonary edema in
WT mice after IR (p < 0.01) but had no effect on lungs
from A2AAR KO mice after IR (Figure 3).
A2AAR activation attenuates cytokine/chemokine 
expression
Pro-inflammatory cytokine/chemokine expression was
measured in BAL fluid of WT and A2AAR KO mouse lungs
after IR, with or without ATL313 treatment. A significant
increase in the production of TNF-α, KC (CXCL1), MIP-2
(CXCL2) and RANTES (CCL5) occurred in both WT and
A2AAR KO mice after IR (Figure 4, p < 0.01). Treatment
with ATL313 significantly attenuated cytokine/chemok-
ine activation after IR in WT mice (p < 0.001) but had no
significant effect in A2AAR KO mice (Figure 4). In addi-
tion, there was no significant production of IL-6, MCP-1
Temporal changes in pulmonary function during reperfusion Figure 1
Temporal changes in pulmonary function during 
reperfusion. Pulmonary artery pressure (A), airway resist-
ance (B), and pulmonary compliance (C) were measured 
throughout 60 min reperfusion in WT sham and IR lungs. 
Lung function is significantly impaired after IR compared to 
sham, and ATL313 significantly attenuated lung dysfunction. 
Open circles, Sham lungs undergoing perfusion only; filled 
circles, IR lungs reperfused after 60 min ischemia; filled trian-
gles, IR lungs treated with ATL313 (30 nM) during reper-
fusion. *p < 0.01 IR vs. all.
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or IFN-γ in WT or A2AAR KO mouse lungs after IR (data
not shown).
Neutrophil infiltration after lung IR is attenuated by A2AAR 
activation
MPO is abundantly present in azurophilic granules of pol-
ymorphonuclear neutrophils and its increased concentra-
tion in BAL fluid is an indicator of neutrophil activation
and migration into alveolar airspaces. MPO content in
BAL fluid was evaluated in WT and A2AAR KO lungs after
IR with or without ATL313 treatment. MPO content was
significantly increased in WT lungs after IR compared to
Sham (Figure 5, p < 0.01). Treatment with ATL313 signif-
icantly reduced MPO content in WT lungs after IR (p <
0.001). In A2AAR KO mice, IR also resulted in significantly
increased MPO content, however ATL313 treatment did
not affect MPO content in these mice (Figure 5).
Discussion
In this study, we investigated the role of A2AAR activation
in mediating protection from lung IR injury utilizing a
buffer-perfused mouse lung model. ATL313-mediated
protection was illustrated by significant reductions in
mean pulmonary artery pressure and airway resistance,
Pulmonary function during reperfusion in A2AAR KO mice Figure 2
Pulmonary function during reperfusion in A2AAR KO 
mice. Pulmonary artery pressure (A), airway resistance (B), 
and pulmonary compliance (C) were measured throughout 
60 min reperfusion in A2AAR KO lungs after IR with or with-
out administration of ATL313. Lung function was significantly 
impaired in A2AAR KO mice, and ATL313 treatment offered 
no protection. Open circles, WT Sham lungs undergoing per-
fusion only; filled circles, WT IR lungs reperfused after 60 
min ischemia; filled triangles, A2AAR KO IR lungs reperfused 
after 60 min ischemia; open triangles, A2AAR KO IR lungs 
treated with ATL313 (30 nM) during reperfusion. *p < 0.01 
WT Sham vs. all.
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Lung IR injury is attenuated by A2AAR activation Figure 3
Lung IR injury is attenuated by A2AAR activation. 
Lung vascular permeability was assessed by measuring BSA 
concentration in BAL fluid (A). Lung edema was assessed by 
measuring wet/dry weight ratio (B). Significant lung injury 
(increased vascular permeability and edema) occurred after 
IR in WT mice which was attenuated by ATL313 treatment. 
Significant lung injury also occurred in A2AAR KO mice after 
IR, but ATL313 had no affect on A2AAR KO lungs. WT Sham, 
WT lungs undergoing perfusion only; WT IR, WT lungs 
undergoing IR; KO IR, A2AAR KO lungs undergoing IR; KO 
IR+ATL313, A2AAR KO IR lungs treated with ATL313 (30 
nM) during reperfusion. *p < 0.001 IR vs. WT Sham; #p < 
0.01 WT IR+ATL313 vs. WT IR.
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and significant improvement in pulmonary compliance
throughout the reperfusion period following ischemia.
Lungs undergoing IR also displayed increased vascular
permeability and pulmonary edema which were signifi-
cantly attenuated by ATL313 treatment. We cannot dis-
count the possibility that the attenuation in vascular
permeability by ATL313 may be in part due to a decrease
in intravascular pressure as well as to changes in endothe-
lial permeability. In addition, A2AAR KO mice demon-
strated significant lung injury and dysfunction, but
ATL313 treatment failed to protect these lungs after IR,
indicating the specificity of ATL313 for A2AAR. The induc-
tion of specific pro-inflammatory cytokines/chemokines
(TNF-α, KC, MIP-2 and RANTES) and increased MPO
content after IR were also significantly attenuated by
A2AAR activation in WT lungs.
The results presented in this study support other reports of
protection from IR injury by specific A2AAR agonists
[16,22,27,35,36]. More importantly, while prior studies
indicate that circulating cells such as platelets and neu-
trophils play a significant role in the anti-inflammatory
effects of A2AAR activation, the present study describes
A2AAR-mediated protection in the absence of circulating
cells. These results suggest that the cellular targets for
ATL313-mediated protection in buffer-perfused lungs are
likely resident lung leukocyte populations including alve-
olar macrophages, neutrophils (including marginated
neutrophils) or T cells. The source of the infiltrating neu-
trophils in alveolar airspaces after IR must be either inter-
stitial or marginated neutrophils in this model. We have
previously shown that a significant number of marginated
neutrophils are retained in buffer-perfused lungs [4].
However, the contribution of other cells, such as epithe-
lial or endothelial cells, to A2AAR-mediated protection
cannot be eliminated. This study suggests that the specific
activation of A2AAR improves pulmonary injury and func-
tion after IR in a non-blood perfused system, thereby indi-
cating the importance of resident pulmonary cells in lung
IR injury.
This study highlights an emerging therapeutic role for the
use of A2AAR agonists, such as ATL313, as a logical exten-
sion of many intrinsic defense mechanisms inasmuch as
Cytokine/chemokine expression after lung IR Figure 4
Cytokine/chemokine expression after lung IR. The expression of TNF-α, MIP-2 (CXCL2), RANTES (CCL5), and KC 
(CXCL1) in BAL fluid were significantly induced after IR in WT and A2AAR KO mice (*p < 0.01 vs. WT Sham). Cytokine/chem-
okine induction was significantly impaired by ATL313 treatment in WT mice but not in A2AAR KO mice (#p < 0.001, WT 
IR+ATL313 vs. WT IR). WT Sham, WT lungs undergoing perfusion only; WT IR, WT lungs undergoing IR; KO IR, A2AAR KO 
lungs undergoing IR; KO IR+ATL313, A2AAR KO IR lungs treated with ATL313 (30 nM) during reperfusion.
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adenosine is known to accumulate in response to inflam-
mation or IR injury. Whereas the exact mechanisms of
protection are complex and poorly understood, treatment
with A2AAR agonists has been associated with inhibition
of inflammatory cytokine release, reduction of apoptotic
injury, and diminution of free radical production [37-39].
In this study, the markedly significant protection offered
by ATL313 in WT mice suggests an important protective
role of A2AARs in lung IR injury, and that specific activa-
tion of A2AAR, and not A1AR, A2BAR or A3AR, has broad
anti-inflammatory effects that attenuate lung IR injury.
Although we anticipated that lung injury and dysfunction
after IR would be worse in A2AAR KO mice, injury and
function in A2AAR KO mice were comparable to WT mice.
One possible explanation for this might be that the buffer-
perfused model of IR injury, or the timeframe utilized (1
hr ischemia and 1 hr reperfusion), does not entail signifi-
cant production of adenosine to result in enhanced anti-
inflammatory effects in WT mice. A second possible expla-
nation is that this model does not entail blood-perfusion
whereby enhanced platelet activation and infiltration of
circulating leukocytes may occur in A2AAR KO mice to
exacerbate injury. However, using a blood-perfused
mouse lung IR model involving left lung hilar clamp (1 hr
ischemia followed by 2 hr reperfusion), we observed a
similar pattern of injury in A2AAR KO mice as compared
to WT mice (data not shown). A third possible explana-
tion, and probably the most likely explanation, is that the
A2AAR does not normally play a significant anti-inflam-
matory role during acute lung IR injury. It is plausible that
activation of other adenosine receptors (A1, A2B and A3),
which are all expressed in the lung [40], may have signifi-
cant, anti-inflammatory roles in the pathogenesis of IR.
For example, it is well documented that A1AR plays a role
in protecting the heart [41] and kidney [42] against IR
injury. However, A1AR antagonism has been shown to be
beneficial in attenuating lung IR injury [43], results which
add to the confusion regarding the role of A1AR in lung
injury. A recent study showed that exposure to endotoxin
results in augmented pro-inflammatory cytokine levels
and increased leukocyte adhesion in A2BAR KO mice [44].
A study by Rivo et al. showed that activation of A3AR may
protect the lung against IR injury [45]. Although it is pos-
sible that enhanced expression of other adenosine recep-
tors could compensate for the lack of A2AAR in the KO
mice, our data suggests that endogenous activation of
A2AAR may not play a significant role in IR injury. The
contribution of other adenosine receptors in the modula-
tion of lung IR injury remains a subject for further investi-
gation.
Previous studies from our group and others have demon-
strated a significant role of alveolar macrophages in the
initiation of lung IR injury [4,46,47]. We have also dem-
onstrated that the intercellular interactions between alve-
olar macrophages and type II epithelial cells are important
events in lung IR injury via activation of specific
cytokines/chemokines such as TNF-α and KC, thereby
leading to enhanced neutrophil chemotaxis [5]. The spe-
cific activation of A2AARs on macrophages has been
shown to attenuate IR injury in other organ systems such
as kidney, liver and heart [21,23,25,48]. However, the role
of A2AAR activation specifically on resident lung cell pop-
ulations after IR has not been previously explored. The
pro-inflammatory cascade in lung IR injury involving
TNF-α has also been previously documented by our group
and others [12,49,50]. These findings highlight a complex
cross-talk between various lung cell populations includ-
ing alveolar macrophages, type II epithelial cells and neu-
trophils in the progression of IR injury. Our findings
suggest that cytokines and chemokines, such as TNF-α, KC
and MIP-2, released by alveolar macrophages and type II
epithelial cells activate neutrophils, which serve as end
effecters of lung IR injury. It is known that neutrophils
progressively infiltrate the transplanted lung after reper-
fusion and contribute to injury by releasing oxygen free
radicals [2]. We also observed that increased alveolar
MPO content after IR was significantly attenuated by
ATL313, indicative of the protective role of A2AARs on res-
ident lung neutrophils. We have previously demonstrated
the presence of marginated neutrophils in buffer-perfused
mouse lungs [4]. A2AARs on these marginated neu-
Lung IR-induced alveolar MPO content is attenuated by  A2AAR activation Figure 5
Lung IR-induced alveolar MPO content is attenuated 
by A2AAR activation. MPO content in BAL fluid was sig-
nificantly induced in lungs from WT and A2AAR KO mice 
after IR (*p < 0.01 vs. WT Sham). MPO content was signifi-
cantly attenuated by ATL313 treatment in WT mice but not 
in A2AAR KO mice (#p < 0.001, WT IR+ATL313 vs. WT IR). 
WT Sham, WT lungs undergoing perfusion only; WT IR, WT 
lungs undergoing IR; KO IR, A2AAR KO lungs undergoing IR; 
KO IR+ATL313, A2AAR KO IR lungs treated with ATL313 
(30 nM) during reperfusion.
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trophils, in conjunction with resident lung leukocytes
such as alveolar macrophages are likely key targets for
ATL313-mediated protection against IR-induced lung
injury.
This study focused on the acute, anti-inflammatory effects
of A2AAR activation. It is plausible, however, that A2AAR-
mediated protection is also a prolonged phenomenon
attenuating the chronic fibroproliferative phase of lung IR
injury. However, due to the inherent limitations of the
acute  ex-vivo, buffer-perfused model, the study of long
term A2AAR-mediated protection is beyond the scope of
the present study. Another limitation of the buffer-per-
fused IR model is the use of hypoxic ventilation to induce
ischemia instead of clamping the lung in an inflated state,
which is utilized in the human lung transplantation.
However, the hypoxic ventilation was used to prevent
atelectasis in the buffer-perfused IR model. Moreover, the
in vivo hilar clamp IR model entails circulating blood and
thus does not specifically address the role of resident lung
cells in lung IR injury, which was the focus of this study.
Conclusion
In summary, our data suggests that attenuation of the
inflammatory cascade by ATL313 activation of A2AARs on
resident lung cells is sufficient in preventing lung injury
and dysfunction after IR. Pulmonary IR injury entails
complex signaling mechanisms involving the intercellular
interactions of various lung cell populations via a pro-
inflammatory cascade. The selective activation of A2AARs
on resident lung leukocyte populations such as alveolar
macrophages, marginated neutrophils, and possibly T
lymphocytes by ATL313 is an anti-inflammatory interven-
tion that inhibits neutrophil activation and subsequent
infiltration and tissue injury. Thus, specific A2AAR activa-
tion may be a promising therapeutic target for the preven-
tion or treatment of pulmonary graft dysfunction in
transplant patients.
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